Breaks Categories: News

WednesdayNov 30, 2022 11:00 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Changes to the Board of Directors

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced the appointments of Dr. Lakshmi P. Kotra and Joseph L. Romano to its board of directors, effective Nov. 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the board of directors. Dr. Kotra, an academic entrepreneur, has contributed to a number of important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He is the recipient of…

Continue Reading

TuesdayNov 29, 2022 3:47 pm

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that its CEO Lance Alstodt will be participating at the RHK Capital Disruptive Growth Conference. The event is slated to take place in New York City from Dec. 5-6, 2022, and feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies. Attendees will include seasoned institutional and accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers and select RHK clients. Interested parties should visit https://ibn.fm/XMA3b to learn more and submit a…

Continue Reading

TuesdayNov 29, 2022 1:35 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT), Sensio Group Partner to Distribute 3D Monitoring System – RoomMate(TM)

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today announced its entry into a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing RoomMate(TM). A 3D infrared monitoring system, RoomMate is a simple and effective solution for looking after patients without intruding on their personal space. The solution allows for a total “anonymized” supervision and monitoring service using infrared 3D technology with no wearables, cameras or devices needed. “We are very excited about this partnership and remarkable proven technology,” said MetAlert Business Development Director Andrew Duncan.…

Continue Reading

TuesdayNov 29, 2022 11:54 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness. Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive)…

Continue Reading

TuesdayNov 29, 2022 10:02 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted basis a new CUSIP number: 18978H201. Approved by company stockholders earlier this year, the reverse stock split is meant to increase the CNSP’s per share trading price and bring the company into compliance with the…

Continue Reading

MondayNov 28, 2022 3:34 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss initiation of coverage of Aditxt with a buy rating and 12-month price target of $4 per share. “Personalized COVID-19 analytics can inform vaccinations, treatments and more. AditxtScore determines the coronavirus infection status of an individual, which can help patients and physicians make a variety of…

Continue Reading

WednesdayNov 23, 2022 11:00 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps to develop the drug, including appointing two new members of the management team with expertise in progressing drugs through the clinical phase and to the market; completing an FDA-required IND in order to move forward…

Continue Reading

TuesdayNov 22, 2022 10:46 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has closed on a private placement with two healthcare-focused institutional investors. The placement included the sale of 1,818,185 INM common shares, which were issued at a purchase price of $3.30 per share (or prefunded warrant in lieu thereof); the shares were priced at-the-market under NASDAQ rules. The announcement also noted that InMed issued unregistered preferred investment options to the investors in the offering to purchase up to 3,272,733 common shares. The offering resulted in approximately $6 million in gross proceeds for…

Continue Reading

MondayNov 21, 2022 12:25 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue, with initial data expected during the first quarter of 2023. “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where…

Continue Reading

MondayNov 21, 2022 11:15 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the upcoming Biotech Showcase conference. The event is slated to take place Jan. 9-11, 2023, in San Francisco in parallel to the J.P. Morgan (“JPM”) 41st Annual Health Care Conference. Reichman will be available to meet potential partners, collaborators and investors. Interested parties should visit https://ibn.fm/p6eOA or https://ibn.fm/tcHsS or contact BiondVax Investor Relations at +972-8-930-2529 or ir@biondvax.com to request a one-on-one appointment. To view the full…

Continue Reading